ArticleNucleic acids research2024
The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods.
Article in Nucleic acids research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 684 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
684 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Genome-wide meta-analysis of quantitatively measured generalized anxiety symptoms in individuals of European ancestry.Nature human behaviour · 2026Pooled it
- The role of AI-assisted drug repurposing in neurological disorders: a systematic review of validation strategies, challenges and opportunities.Journal of nanobiotechnology · 2026Pooled it
- Article
- Diethyl Phthalate (DEP) as a potential osteosarcoma risk factor: a multi-omics study integrating network Toxicology, single-cell RNA sequencing, and molecular docking.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Network toxicology and molecular docking reveal the mechanistic basis of bisphenol A-mediated cholestatic liver injury.Toxicology reports · 2026Article
- Identification and biological evaluation of benzimidazole-based compounds as novel TGFβR1 inhibitors.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- Article
- AI Accelerated Chemical Screening Integrates ChemBERTa to Identify Repositionable CASP4 Inhibitors via MD Simulations and MM/PBSA Analysis.Journal of chemical information and modeling · 2026Article
- Drug repurposing in hereditary ataxia.npj drug discovery · 2026Review
- CAPRICHO: Interpretable Quality Flagging and Flexible ChEMBL Bioactivity Curation for QSAR Modeling.Journal of chemical information and modeling · 2026Article
- Article
- Commit: BitBIRCH: efficient clustering of large molecular libraries.Digital discovery · 2026Article
- Artificial Intelligence in Photodynamic Therapy: From Molecular Design of Photosensitizers to Intelligent Delivery, Adaptive Dosimetry, and Personalized Prognostication of Results.International journal of molecular sciences · 2026Review
- Pharmacological stratification of public bioactivity databases: a reusable, OECD-anchored curation and benchmarking framework demonstrated for opioid receptors.Digital discovery · 2026Article
- Machine Learning-Guided Identification of Madecassoside as a Potential RAD51 Modulator That Sensitizes Breast Cancer Cells to Cisplatin.Chemical biology & drug design · 2026Article
- Integrated bioinformatics analyses and cell line experiments implicate miR-33a-5p/HIF1A in the cellular response to celastrol in lung adenocarcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Disclosing pathogenic processes of monkeypox (MPOX) and drug repurposing through host-transcriptomics analysis.PLoS neglected tropical diseases · 2026Article
- AI-driven discovery of natural product-derived FAK1 inhibitors for idiopathic pulmonary fibrosis.Molecular diversity · 2026Article
- Subtractive proteomics-driven identification of AgrA and structure-guided discovery of phytochemical and marine natural products as novel anti-quorum sensing therapeutic leads against Enterococcus faecium.Molecular diversity · 2026Article
- Identification of YES1 Inhibitors From Approved Drugs Using a Multimodal Deep Learning Framework.Molecular informatics · 2026Article
624 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
ChEMBL (https://www.ebi.ac.uk/chembl/) is a manually curated, high-quality, large-scale, open, FAIR and Global Core Biodata Resource of bioactive molecules with drug-like properties, previously described in the 2012, 2014, 2017 and 2019 Nucleic Acids Research Database Issues. Since its introduction in 2009, ChEMBL's content has changed dramatically in size and diversity of data types. Through incorporation of multiple new datasets from depositors since the 2019 update, ChEMBL now contains slightly more bioactivity data from deposited data vs data extracted from literature. In collaboration with the EUbOPEN consortium, chemical probe data is now regularly deposited into ChEMBL. Release 27 made curated data available for compounds screened for potential anti-SARS-CoV-2 activity from several large-scale drug repurposing screens. In addition, new patent bioactivity data have been added to the latest ChEMBL releases, and various new features have been incorporated, including a Natural Product likeness score, updated flags for Natural Products, a new flag for Chemical Probes, and the initial annotation of the action type for ∼270 000 bioactivity measurements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.